Subscribe to our News Updates & Alerts
ASX AGN:
A$
Home
About
Company Overview
Our Mission
Board & Management
Clinical Advisory Committee
Partnerships
Investors
Share Information
Announcements & Reports
ASX Announcements
Corporate Directory
Corporate Governance
Technology
The Science
Development
Publications
Media
News & Media
Contact
2023
22 Sep 2023
Perth developed drug, ARG-007, shows encouraging signs to prevent impacts of traumatic brain injuries
Reference:
The West Australian
06 Sep 2023
Strokes cost the Australian economy billions, but these biotech players could change that
Reference:
The Australian
06 Sep 2023
90 Seconds With… Dr Liz Dallimore, Argenica Therapeutics (ASX:AGN)
Reference:
Stockhead
05 Sep 2023
The right medical combination
Reference:
Market Open
23 Oct 2023
$AGN Argenica Therapeutics is developing drugs which focus on preventing brain injury
Reference:
The Market Bull
18 Oct 2023
Groundbreaking: This drug could be ‘significantly effective’ at treating brain damage in newborns
Reference:
Stockhead
05 Oct 2023
Perth stroke treatment hits phase 2
Reference:
Medical Forum
04 Oct 2023
Argenica Therapeutics greenlit to launch Phase II trials into stroke treatment
Reference:
Clinical Trials Arena
06 Nov 2023
Stroke Trial – Jenny Seaton
Reference:
Curtin FM
03 Nov 2023
Data shows Argenica’s drug inhibits another main cause of Alzheimer’s disease
Reference:
Stockhead
Subscribe to our mailing list to stay up to date with Argenica Therapeutics
First Name
*
Last Name
*
Email
*
CAPTCHA
Home
About
Company Overview
Our Mission
Board & Management
Clinical Advisory Committee
Partnerships
Investors
Share Information
Announcements & Reports
ASX Announcements
Corporate Directory
Corporate Governance
Technology
The Science
Development
Publications
Media
News & Media
Contact
Privacy Policy
Terms & Conditions
